Navigation Links
AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
Date:4/22/2009

nformation on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... DIEGO , July 28, 2014 ... cultivation technologies, today announced the appointment of biotechnology veteran ... of the board of directors. Levine replaces Cynthia ,CJ, ... immediately. She will remain chairman of the company,s board ... on Sapphire Energy,s mission to deliver commercial scale algae-based ...
(Date:7/28/2014)... July 28, 2014 The Workgroup for ... on the use of health IT to create efficiencies ... Plan Identifier (HPID) Workgroup has developed an issue ... Plan and Payer?” The HPID Workgroup, a part of ... the Centers for Medicare and Medicaid Services (CMS) to ...
(Date:7/28/2014)... “2014 Deep Research Report ... a professional and in-depth research report on ... introduces Lubricant basic information, including Lubricant definition, ... industry overview. This research covers the international ... well as global industry analysis covering macroeconomic ...
(Date:7/28/2014)... According to a new market research report ... and Joint) Market (By Technology - Stem Cell ... Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic ... Share, Growth, Trends and Forecast, 2013 - 2019" ... was valued at USD 2.6 billion in 2012 ...
Breaking Biology Technology:Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4
... tumor,s vulnerability yields durable responses in Phase I/II ... ... 21 Systems Medicine, LLC (SM),a wholly-owned subsidiary of Cell Therapeutics, ... phase I trial,combining cisplatin with brostallicin in patients with solid tumors ...
... Nov. 21 Syngenta and the Royal,Society of Chemistry ... to help promote the economic and social development of,the ... continent,is being established initially in Kenya. Its purpose is ... to achieve greater levels of,innovation and scientific development., ...
... paper to be published Nov. 22 in the online ... of Wisconsin-Madison researchers reports the genetic reprogramming of human ... cells., The finding is not only a critical scientific ... landscape of stem cell biology as human embryos may ...
Cached Biology Technology:Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers 2Brostallicin Trial Data Demonstrates Encouraging Anti-tumor Activity in Patients With Chemotherapy-Resistant Cancers 3Syngenta and The Royal Society of Chemistry Launch African Science Initiative 2Syngenta and The Royal Society of Chemistry Launch African Science Initiative 3UW-Madison scientists guide human skin cells to embryonic state 2UW-Madison scientists guide human skin cells to embryonic state 3
(Date:7/28/2014)... U.S. cities that have seen an increase in so-called ... closures, overwhelmed storm drains and compromised infrastructure--are on the ... , This nuisance flooding, caused by rising sea levels, ... and 925 percent since the 1960s. , The report, ... the United States, also finds Annapolis and Baltimore, Maryland, ...
(Date:7/28/2014)... There is no cure for Alzheimer,s disease and other ... step closer to finding treatment. , University of Washington ... stop the harmful changes of the body,s normal proteins ... as Alzheimer,s, Parkinson,s, heart disease, Type 2 diabetes and ... as they shift from their normal state into an ...
(Date:7/28/2014)... findings of a new study suggest two ways to effectively ... as well in obese women, compared to women of a ... one-size-fits-all method, researchers say, but as the population has increased ... works for obese women. Studies have consistently found that obesity ... which may in turn affect how well the pill prevents ...
Breaking Biology News(10 mins):NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3Strategies identified to improve oral contraceptive success with obese women 2
... among the authors of a new paper that describes ... when and how to use an environmental strategy known ... assistant professors of biology, and Alejandro Camacho, associate professor ... that produced the paper, which appears in this week,s ...
... are several risk factors for the development of Alzheimer,s ... of studies linking these risk factors with Vitamin D ... Journal of Alzheimer,s Disease (May 2009) by ... Health Research Center (SUNARC) suggests that further investigation of ...
... wounded during combat, surgeons must focus on reducing infection ... improve the repair and regeneration processes are being developed ... not being moved quickly enough into military trauma centers. ... for Advanced Bioengineering for Soldier Survivability want to change ...
Cached Biology News:Notre Dame researchers describe new tool for evaluating 'managed relocations' 2Notre Dame researchers describe new tool for evaluating 'managed relocations' 3Is vitamin D deficiency linked to Alzheimer's disease and vascular dementia? 2New center at Georgia Tech aims to improve recovery of soldiers with severe injuries 2New center at Georgia Tech aims to improve recovery of soldiers with severe injuries 3
... H3 (Lys 4) Immunogen: ... ...RT[ Ac K]Q... in which [ Ac ... human histone H3 Accession ... Weight: Mr ~17kDa ...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
b-Catenin (pSer675), phospho-specific...
BDFastImmune? IFN-gamma /CD69/CD4/CD3 Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: